Tirzepatide Reduces Albuminuria in Patients with T2D: Post-hoc Pooled Analysis of SURPASS 1-5
Diabetologie und Stoffwechsel · 01.04.2024 · 19 (S 01 S 01) · S75
DOI: 10.1055/s-0044-1785384 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetologie und Stoffwechsel, erschienen am 01.04.2024. Verfasst von Hiddo L Heerspink und 9 weiteren Autor:innen. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Abstract (Originalsprache)
Does tirzepatide (5, 10, 15 mg) reduce urine albumin-creatinine ratio (UACR) compared to placebo or other diabetes medications? Methods : In this post-hoc analysis, UACR (% difference) for TZP (5, 10, 15 mg) vs comparators (COMPs) was analysed. Analyses were conducted in the pooled entire SURPASS 1-5 population and populations pooled by COMP: placebo (SURPASS 1 & 5); active (SURPASS 2 [semaglutide 1 mg] & SURPASS 3-4 [insulins]); and insulins. In each pooled population, data were examined in all patients and in subgroups defined by baseline UACR ≥30 mg/g or eGFR
Zitieren
APA
Heerspink, H. L., Tuttle, K. R., Pavo, I., Haupt, A., Yang, Z., Wiese, R. J., Hemmingway, A., Cherney, D. I., Sattar, N., & Jacob, S. (2024). Tirzepatide Reduces Albuminuria in Patients with T2D: Post-hoc Pooled Analysis of SURPASS 1-5. Diabetologie und Stoffwechsel, 19(S 01 S 01), S75. https://doi.org/10.1055/s-0044-1785384
Vancouver
Heerspink HL, Tuttle KR, Pavo I, Haupt A, Yang Z, Wiese RJ, et al. Tirzepatide Reduces Albuminuria in Patients with T2D: Post-hoc Pooled Analysis of SURPASS 1-5. Diabetologie und Stoffwechsel. 2024;19(S 01 S 01):S75. doi:10.1055/s-0044-1785384
BibTeX
@article{Heerspink2024,
author = {Heerspink, Hiddo L and Tuttle, Katherine R and Pavo, Imre and Haupt, Axel and Yang, Zhengyu and Wiese, Russell J and Hemmingway, Andrea and Cherney, David I and Sattar, Naveed and Jacob, Stephan},
title = {Tirzepatide Reduces Albuminuria in Patients with T2D: Post-hoc Pooled Analysis of SURPASS 1-5},
journal = {Diabetologie und Stoffwechsel},
year = {2024},
volume = {19},
number = {S 01 S 01},
pages = {S75},
doi = {10.1055/s-0044-1785384}
}
EUVIMED